GSK plc (NYSE:GSK) Shares Sold by Hall Laurie J Trustee

Hall Laurie J Trustee decreased its stake in GSK plc (NYSE:GSK) by 24.3% in the 4th quarter, HoldingsChannel reports. The institutional investor owned 1,075 shares of the pharmaceutical company’s stock after selling 346 shares during the period. Hall Laurie J Trustee’s holdings in GSK were worth $37,000 as of its most recent SEC filing.

A number of other hedge funds have also recently modified their holdings of the stock. Eastern Bank purchased a new stake in GSK in the third quarter valued at $26,000. Sunbelt Securities Inc. lifted its holdings in shares of GSK by 73.8% in the 3rd quarter. Sunbelt Securities Inc. now owns 711 shares of the pharmaceutical company’s stock valued at $29,000 after purchasing an additional 302 shares during the last quarter. Concord Wealth Partners boosted its position in shares of GSK by 231.8% in the 3rd quarter. Concord Wealth Partners now owns 783 shares of the pharmaceutical company’s stock valued at $32,000 after purchasing an additional 547 shares during the period. ST Germain D J Co. Inc. grew its stake in GSK by 195.5% during the 4th quarter. ST Germain D J Co. Inc. now owns 789 shares of the pharmaceutical company’s stock worth $27,000 after buying an additional 522 shares during the last quarter. Finally, Fortitude Family Office LLC acquired a new position in GSK during the third quarter worth approximately $42,000. 15.74% of the stock is owned by hedge funds and other institutional investors.

GSK Stock Up 0.0 %

Shares of NYSE:GSK opened at $33.46 on Monday. The company has a market cap of $69.34 billion, a price-to-earnings ratio of 21.72, a PEG ratio of 1.44 and a beta of 0.63. GSK plc has a fifty-two week low of $31.72 and a fifty-two week high of $45.92. The firm’s 50-day simple moving average is $34.02 and its 200-day simple moving average is $37.98. The company has a quick ratio of 0.53, a current ratio of 0.81 and a debt-to-equity ratio of 0.98.

GSK Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Thursday, January 9th. Stockholders of record on Friday, November 15th were paid a dividend of $0.3928 per share. This represents a $1.57 dividend on an annualized basis and a dividend yield of 4.70%. This is an increase from GSK’s previous quarterly dividend of $0.38. The ex-dividend date of this dividend was Friday, November 15th. GSK’s dividend payout ratio is 96.10%.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on the company. Guggenheim downgraded GSK from a “buy” rating to a “neutral” rating in a report on Thursday, October 31st. StockNews.com upgraded shares of GSK from a “buy” rating to a “strong-buy” rating in a research note on Monday, January 13th. Deutsche Bank Aktiengesellschaft lowered shares of GSK from a “buy” rating to a “hold” rating in a research note on Friday, November 15th. Finally, Jefferies Financial Group downgraded shares of GSK from a “buy” rating to a “hold” rating and decreased their target price for the stock from $53.00 to $39.50 in a research note on Tuesday, November 12th. Seven research analysts have rated the stock with a hold rating and four have assigned a strong buy rating to the company’s stock. According to MarketBeat.com, GSK presently has an average rating of “Moderate Buy” and an average price target of $43.25.

GSK Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.